Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome
Renju V Raj, Mehdi Hamadani, Aniko Szabo, Marcelo C Pasquini, Nirav N Shah, William R Drobyski, Bronwen E Shaw, Wael Saber, J Douglas Rizzo, James Jerkins, Timothy S Fenske, Anita D'Souza, Binod Dhakal, Chao Zhang, Steve Konings, Parameswaran N Hari, Saurabh Chhabra, Renju V Raj, Mehdi Hamadani, Aniko Szabo, Marcelo C Pasquini, Nirav N Shah, William R Drobyski, Bronwen E Shaw, Wael Saber, J Douglas Rizzo, James Jerkins, Timothy S Fenske, Anita D'Souza, Binod Dhakal, Chao Zhang, Steve Konings, Parameswaran N Hari, Saurabh Chhabra
Abstract
T cell-replete post-transplant cyclophosphamide (PTCy)-based protocols have led to increasing use of haploidentical allogeneic hematopoietic cell transplantation (haploHCT). With this approach, bidirectional alloreactivity causing nonengraftment or severe graft-versus-host disease (GVHD) is no a longer major barrier to haploHCT. PTCy eliminates alloreactive lymphocytes but spares CD34+ stem cells and regulatory T lymphocytes, resulting in reliable hematopoietic recovery with relatively low incidence of GVHD. The immediate post-haploHCT course, usually before PTCy administration, is often complicated by cytokine release syndrome (CRS). The predictors of CRS and its effect on outcomes post-transplant have not been fully ascertained. We analyzed the outcomes of 66 patients who received haploHCT at our institution. Using published CRS criteria we identified 48 patients who developed CRS. In multivariate analysis peripheral blood grafts were significantly associated with grade ≥ 2 CRS, compared with bone marrow. Grade ≥ 2 CRS (compared with grade < 2) was not associated with differences in overall survival or nonrelapse mortality. Severe CRS was associated with a statistically nonsignificant trend toward higher incidences of grades III to IV acute GVHD, especially in the context of peripheral blood grafts. CRS is a common complication after T cell-replete peripheral blood haploHCT, but post-transplant survival outcomes may not be affected in those with severe CRS.
Keywords: Cytokine release syndrome; Haploidentical; Post-transplant cyclophosphamide.
Copyright © 2018 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Source: PubMed